• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    ProMIS Neurosciences to Present Data from Alzheimer's Disease Program

    Bryan Mc Govern
    Jul. 05, 2017 09:54AM PST
    Biotech Investing

    ProMIS Neurosciences announced it will present preclinical data for its lead product candidate, PMN310.

    ProMIS Neurosciences (TSX:PMN) announced it will present preclinical data for its lead product candidate, PMN310, at the Alzheimer’s Association International Conference (AAIC) in London in July.
    As quoted in the press release:

    Johanne Kaplan, Ph.D., ProMIS Chief Development Officer, will present the data and chair the associated session, entitled Preclinical: Basic Therapeutics – Targeting Amyloid or Tau.
    The presentation by Kaplan (et al.), entitled Targeting of toxic amyloid-beta oligomer species by monoclonal antibody PMN310:  Precision drug design for Alzheimer’s disease describes the use of ProMIS’ proprietary discovery engine for the identification and generation of monoclonal antibodies against specific targets on toxic forms of amyloid beta (Ab), a recognized root cause of Alzheimer’s.
    Commenting on the presentation, Dr. Kaplan stated, “Antibody PMN310 was selected as our lead product for development on the basis of its ability to selectively target and neutralize toxic Ab oligomers with no significant off-target binding to Ab monomers or fibrils. These characteristics distinguish PMN310 from other Ab antibodies currently undergoing clinical trials, and are designed to achieve optimal efficacy and safety.”

    Click here to read the full press release.

    Source: www.newswire.ca

    promis neurosciencespreclinical dataclinical trialsproduct candidate
    The Conversation (0)

    Go Deeper

    AI Powered
    Man holds hand to head as fragments break off representing Alzheimer's disease.

    Alzheimer’s Disease Treatment Stocks: 3 Biggest NASDAQ Companies

    Actinogen

    Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×